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Abstract
Background: To detect the expression of isocitrate dehydrogenase 1 (IDH1) and transformation-related protein 53 
(p53) in osteosarcoma and analyze the correlation between them and the clinico-pathological features.
Methods: The expressions of IDH1 and p53 were detected in human osteosarcoma cell lines (MG-63 and U2OS) by 
immunocytochemistry, Real-time PCR and Western Blotting. The expressions of IDH1 and p53 in formalin-fixed 
paraffin-embedded tissue sections from 44 osteosarcoma patients were determined by immunohistochemistry, and 
the correlation between them and clinicopagthological features were analyzed. None of these patients received 
chemotherapy prior to surgery.
Results: IDH1 is detected in osteosarcoma cell lines and biopsies. IDH1 expresses higher in U2OS cells with wild type 
p53 than in MG-63 cells with mutation p53. IDH1 correlates with histological Rosen grade and metastasis negatively. 
P53 correlates with histological Rosen grade, metastasis and overall survival in clinical osteosarcoma biopsies. 
Osteosarcoma patients with High IDH1 expression have a very high p53 expression.
Conclusion: IDH1 may correlate with p53 and be a candidate biomarker for osteosarcoma correlate with histological 
Rosen grade and metastasis.
Background
Osteosarcoma (OS) is the most current primary malig-
nant bone tumor in children and adolescents. Presently,
60% of the affected patients are cured by wide resection
of the tumor and aggressive adjuvant chemotherapy [1,2].
However, around 40% of the individuals with metastases
still emerge which normally exhibit resistance to cytostat-
ics and acquire "second malignancies" [3]. The identifica-
tion of biomarkers linked to clinicopagthological features
and development of this disease is crucial for the diagno-
sis and treatment of these patients [4,5].
Genetic alterations caused either by lost of heterozy-
gosity or by mutations have been reported in osteosar-
coma. Such alterations can occur in tumor suppressor
genes, such as tumor protein 53(p53) and phosphates and
tensin homolog (PTEN). The p53 mutations occurs com-
monly in primary osteosarcoma [6]. It is implicated in the
pathogenesis of various human malignancies through loss
of function mutations [7,8]. P53 contributes to the devel-
opment, life expectancy, and overall fitness of an organ-
ism except for its role in protecting against cancer
development [9]. PTEN is known to be the most highly
mutated tumor suppressor gene after p53 [10]. It plays an
important role in regulating proliferation, migration, sur-
vival, cell invasion and tumor angiogenesis [11,12]. Free-
man et al. [13] reported that loss of PTEN was a common
occurrence in osteosarcoma. It was further demonstrated
that PTEN can control p53 half-life independent via a
currently unknown mechanism [14]. In addition, muta-
tions of tumor-suppressor retinoblastoma gene (Rb) in
osteosarcoma are associated with a poor prognosis [15].
However, none of these alterations can characteristically
reflect the biologic nature or clinical features of all osteo-
sarcomas.
IDH1 is a cytosolic NADP-dependent isocitrate dehy-
drogenase. It catalyzes decarboxylation of isocitrate into
alpha-ketoglutarate [16]. Shechter et al. [17] described
that the activity of IDH1 is coordinately regulated
through the cholesterol and fatty acid biosynthetic path-
ways, suggesting that IDH1 provides the cytosolic
NADPH required by these pathways. Memon et al. [18]
found that expression of IDH1 was downregulated in a
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poorly differentiated bladder cancer cell line compared
with a well-differentiated bladder cancer cell line. Tissue
biopsies of late-stage bladder cancers also showed IDH1
downregulation compared with early-stage bladder can-
cers. Yan et al. [19] described that mutations of NADP
(+)-dependent isocitrate dehydrogenases encoded by
IDH1 and IDH2 occur in a majority of several types of
malignant gliomas.
Interestingly, Parsons et al. [20] found that IDH1 muta-
tions in human glioblastoma had a very high frequency of
p53 mutation. Mutation of the IDH1 gene was also
strongly correlated with a normal cytogenetic status [21].
IDH1 appears to function as a tumor suppressor that,
when mutationally inactivated, contributes to tumorigen-
esis [21,22]. But, there is no study on the expression of
IDH1 in osteosarcoma. As to the previous study on IDH1
and p53, we are also curious intensively about the correla-
tion between IDH1 and p53. So, we developed a study to
characterize the expression and significance of IDH1 and
p53 in osteosarcoma cell lines (MG63 and U2OS) as well
as in clinical patient biopsies.
Methods
Cell lines and cell culture
The human osteosarcoma (OS) cell lines MG63 and
U2OS (obtained from ATCC through LGC Promochem,
Wesel, Germany) were cultured in RPMI 1640 media
(Sigma, USA) with 10% fetal bovine serum (Amresco,
USA) and antibiotics. Cells were cultured according to
standard techniques in cell culture flasks in a humidified
incubator in 5% CO2 atmosphere.
Immunocytochemistry
Cell lines were grown on coverslips treated with the
appropriate growth media in 24 well cluster plates. Cells
were fixed in 2% formaldehyde in 0.1 mol/L phosphate-
buffered saline (PBS, pH 7.4) for 20 min at room temper-
ature and subsequently washed three times in PBS. Cov-
erslips were permeabilized with 0.1% Triton X-100 for 15
min and blocked in 3% H2O2-methyl alcohol for 15 min.
The coverslips were incubated with anti-IDH1 rabbit
polyclonal antibody (protein technology group, USA) in
blocking buffer overnight at 4°C. Coverslips were then
incubated with an anti-rabbit secondary antibody and
peroxidase-conjugated strepavidin-biotin complex (Santa
Cruz, CA, USA) at 37°C for 45 min at room temperature
in the dark [23]. Immunoreactivity was visualized with
diaminobenzidine (DAB) (Zymed, South San Francisco,
CA). Negative controls were obtained by omitting the
primary antibody. Slides were scanned using a micros-
copy (Carl Zeiss AG, Germany), images were recorded
using a digital camera (DC 500, Leica) and the Leica FW
4000 software and images were processed using Adobe
Photoshop.
Real-time PCR
Cellular total RNA from OS cells was extracted with TRI-
ZOL Reagent (Invitrogen, Carlsbad, CA, USA). The con-
centration of RNA was determined by the absorbance at
260 nm and the purity was determined by the 260/280
ratio with a BioPhotometer(Eppendorf, Hamburg, Ger-
many). For each reaction, 1 μg RNA was reverse-tran-
scribed with random primer by ReverT ra Ace (T oyobo,
Osaka, Japan). RNA quality and efficiency of reverse tran-
scription were examined by PCRs from each 1 μl cDNA
according to the manufacturer's recommendations [24].
The mRNA expression of IDH-1, p53 and internal control
geneβ-actin was quantified by Real-time PCR Detection
System (SLAN, HONGSHI) with SYBR Green I (Toyobo,
Osaka, Japan). As PCR was performed according to stan-
dard procedures [24,25] after optimization, PCR-reac-
tions were within the exponential range of amplification.
The gene-specific exon-spanning PCR primer pair for
IDH1 was 5'-TCAGTGGCGGTTCTGTGGTA-3',5'-
CTTGGTGACTTGGTCGTTGGT-3', and for p537-8 was
5'-CAGCCAAGTCTGTGACTTGCACGTA C-3',5'-
CTATGTCGAAAAGTGTTTCTGTCATC-3', and for β-
actin was 5'-GTCCACCGCAAATGCTTCTA-3',5'-
TGCTGTCACCTTCACCGTTC-3'. The sequences of
the primers were checked by Nucleotide BLAST for spe-
cific gene amplification. Omission of cDNA template was
used as a negative control. Triplicate measurements were
made of all genes in each patient and data of mean were
used. For relative quantification of genes expression level,
standard curves were built by considering at least three
points of a ten-fold dilution series of cDNA in water. Rel-
ative gene expression data are given as the n-fold change
in transcription of the target genes normalized to the
endogenous control in the same sample.
Protein extraction and Western blot
Lysates of cells were prepared using lysis buffer from the
Dual-Luciferase assay kit (Promega) according to the
manufacturer's recommendations. The lysates were col-
lected and centrifuged at 12,000 g for 10 min at 4°C. The
protein in the supernatants were pooled together and
stored at -80°C until concentration analyzed by the BCA
Protein Assay Kit (Sangon, Shanghai, China). After being
heated at 99°C for 5 min in loading buffer, equal volume
of tissue lysates (40 μg of protein) were then loaded for
sodium dodecyl sulphate-polyacrylamide gel electopho-
resis (SDS-PAGE) analysis and subsequently electrotrans-
ferred from the gels onto a polyvinylidene difluoride
(PVDF) membranes (Millipore, MA, USA). The trans-
ferred membranes were blocked with 5% skim milk in
Tris-buffered saline with 0.05% Tween (TBST) and
washed six times in TBST. IDH1 and p53 proteins were
detected by the rabbit polyclonal antibody for IDH1 (pro-
tein technology group, USA) or p53 (Santa Cruz, CA,Hu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:43
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USA). β-actin proteins were recognized by the β-actin-
specific monoclonal mouse IgG (Santa Cruz, CA, USA).
Antibodies were diluted according to the manufacture
direction and were incubated overnight at 4°C followed
by incubating with peroxidase-conjugated goat anti-rab-
bit immunoglobulin (Santa Cruz, CA, USA, 1:2000) in
TBST for 1 h. Signals were developed using enhanced
chemiluminescent reagent (Pierce Biotechnology, Rock-
ford, IL, USA). β-actin is used as the internal loading con-
trol. The band intensity was analyzed using Quantity One
software (Bio-Rad, Hercules, and CA). Relative expres-
sion was calculated as the intensity ratio of target protein
to that of β-actin.
Tissue specimens and clinical data
Fifty-one formalin-fixed, paraffin-embedded osteosar-
coma biopsies (before the administration of neo-adjuvant
chemotherapy) were collected according to the Chinese
national ethical guidelines ('Code for Proper Secondary
Use of Human Tissue', Chinese Federation of Medical
Scientific Societies). Because of limitations in available
tumor material and following up information, only 44 of
these osteosarcoma tumor samples including 32(72.7%)
males and 12(27.3%) females with mean age(M ± SD) of
25.25 ± 13.61 years (range 9-61) were amenable for use in
this study . Patients were followed until death from dis-
ease, or until the latest clinical therapy at the end of this
study. The mean following-up time(M ± SD) were 4.26 ±
1.99 years (range 0.5-9.0). All patients consisted with the
diagnostic criteria of osteosarcoma defined in the World
Health Organization classification. Written informed
consent was obtained from each patient before entering
into this study. Clinical information was available in Table
1.
Immunohistochemistry for biopsies
Sections were cut from formalin-fixed, paraffin-embed-
ded granulation tissue. They were hydrated through
graded alcohols. For antigen unmasking, sections were
treated in trypsin solution for 10 min at 37°C. Sections
were then washed with deionized water and incubated
with 3% H2O2 for 5 min. They were incubated in anti-
IDH1 mAb (protein technology group, USA) or anti-p53
mAb (Santa Cruz, CA, USA) for 1 h at room temperature,
followed by secondary antibody and peroxidase-conju-
gated strepavidin-biotin complex (Santa Cruz, CA, USA)
at 37°C for 30 min. Immunoreactivity was visualized with
diaminobenzidine (DAB) (Zymed, South San Francisco,
CA). Negative controls were obtained by omitting the
primary antibody.
Evaluation of immunohistochemistry
The slides were evaluated under the microscope. The
percentage of cells showing positive nuclear staining for
p53 was calculated by reviewing the entire spot. For
IDH1, cytoplasmic immunostaining was considered to be
positive. The staining patterns were classified into scales
on the percentage of cells with positive staining [26,27]: 0,
absence of nuclear (or cytoplasmic) stained cell; 1, <10%
positive cells; 2, 10-25% positive cells; 3, 26-50% positive
cells; 4, 51-75% positive cells; 5, >75% positive cells. For
statistical analysis, osteosarcoma patients were also
grouped as either low-staining group (scale 0-3: positive
staining ≤ 50%) or high-staining group (scale 4, 5: positive
staining >50%). Biopsy Stained less than 10% was consid-
ered as a negative result, while stained more than 10%
was considered as a positive one. At least 5 separated foci
of neoplastic infiltration in each biopsy were analyzed.
Assessment of Immunostaining intensity was completed
by three independent observers. Slides were scanned
using a microscopy (Carl Zeiss AG, Germany), images
were recorded using a digital camera (DC 500, Leica) and
the Leica FW 4000 software and images were processed
using Adobe Photoshop.
Statistical analysis
All statistical analyses were performed using the SPSS
13.0 software package for Windows (SPSS Inc., Chicago,
IL, USA). The values for the description of the statistical
significance of IDH1 or p53 expression in different osteo-
sarcoma cell lines were calculated by independent, two-
tailed Student's t-tests after the Levine's Test for Equality
of Variances. Mann-Whitney U was used for unnormal
continuous variables. Categorical variables were analyzed
by the Pearson Chis-square test and Fisher's exact test.
Associations were assessed by Pearson correlation coeffi-
cient for normal data or Spearman's correlation coeffi-
cient for nonnormal data. Kaplan-Meier test was used for
analysis of survival versus IDH1 and survival versus p53
expression. P < 0.05 was considered as statistically signifi-
cant. P < 0.01 was considered as statistically highly signif-
icant.
Results
IDH1 expresses higher in U2OS compared with in MG63
Expression of IDH1 is specifically detected in the cyto-
plasm of both osteosarcoma cell lines U2OS and MG63
( F i g .  1 ) .  T h e  e x p r e s s i o n  o f  I D H 1  m R N A  i s  h i g h e r  i n
U2OS than in MG63, and P < 0.01(Fig. 2). The western
blotting result(Fig. 3A, Fig. 3C) shows that IDH1 is highly
expressed in U2OS(P < 0.01), and these results corrobo-
rate the immunocytochemistry(Fig. 1).
Expression of p53 in U2OS and MG63
Consistent with data published previously [28,29]; our
MG63 demonstrates no detectable p53 while U2OS dem-
onstrates high expressed p53. The result is shown in Fig.
3B.Hu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:43
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IDH1 correlates with histological Rosen grade and 
metastasis in clinical osteosarcoma biopsies
IDH1 mainly locates on the cytoplasm (Such as Fig. 1A,
Fig. 4A, and Fig. 5A). It's positive expression was identi-
fied using immunohistochemistry in 40 of 44 (90.9%)
osteosarcoma tumors, of which 23 of 44 (52.2%) exhibits
high staining (Table 2). The average IDH1 immunostain-
ing percentage is 53.57%(SD: 28.99%, range from 8% to
100%). The average score is 3.59 (SD: 1.22, range from 1
to 5). IDH1 expresses higher in low Rosen grade osteosar-
coma vs. high Rosen grade osteosarcoma [30-32] (Fig. 4,
Fig. 5, Fig. 6, and Fig. 7). IDH1 correlates with metastasis
Table 1: Clinical Features
Features Total(N) Percentage
Age(year)
<12 3 6.8%
13--20 14 31.8%
21--30 8 18.2%
31--40 14 31.8%
41- 5 11.4%
Sex
Male 32 72.7%
Female 12 27.3%
Localization of primary tumor
Distal femur 13 29.5%
Proximal tibia 11 25.0%
Humerus 3 6.8%
Tibia diaphysis 5 11.4%
Femur diaphysis 7 15.9%
Other 5 11.4%
Histological type
Osteoblastic 29 65.9%
Small cell 1 2.3%
Chondroblastic 6 13.6%
Teleangetatic 1 2.3%
Round cell 2 4.5%
Fibroblastic 4 9.1%
Mixed 1 2.3%
Histological Rosen grade*
15 1 1 . 3 %
2 16 36.4%
3 16 36.4%
47 1 5 . 9 %
1+2 21 47.7%
3+4 23 52.3%
Metastasis
no 23 53.3%
lung 17 38.6%
other 4 9.1%
*As described previously [30-32], Grade 1: <50% tumor necrosis; Grade2: 50% to 90% tumor necrosis; Grade 3: > 90% tumor necrosis;Grade 
4: 100% tumor necrosis.1+2: low grade; 3+4: high grade.Hu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:43
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negatively (P = 0.016, r = -0.361). There is no significant
correlation between IDH1 expression and overall survival
(P = 0.342) (Fig. 8).
P53 correlates with histological Rosen grade, metastasis 
and overall survival in clinical osteosarcoma biopsies
P53 mainly locates on the nuclear (Such as Fig 4B, Fig
4D), Its positive expression is identified using immuno-
histochemistry in 37 of 44 (84.1%) osteosarcoma tumors,
of which 19 of 44 (43.2%) exhibits high staining (Table 2).
The average p53 immunostaining percentage is
47.25%(SD: 28.82%, range from 4.5% to 100%). The aver-
age score is 3.18 (SD: 1.35, range from 1 to 5). P53
expresses higher in low Rosen grade osteosarcoma (Fig. 4,
Fig. 5, Fig. 6, Fig. 7). P53 correlates with metastasis nega-
tively (P = 0.001, r = -0.473). High-expression p53
patients have better survival than low-expression p53
patients do (P = 0.019) (Fig. 9).
IDH1 correlates with p53 in clinical osteosarcoma biopsies
There is no significant difference between IDH1 and p53
in clinical osteosarcoma biopsies. Positive correlation
between IDH1 and p53 expression is demonstrated in our
study (Table 2, Fig. 4, and Fig. 5).
Discussion
IDH1 catalyzes decarboxylation of isocitrate into alpha-
ketoglutarate 16. Shechter et al. [17] described that activ-
ity of IDH1 is coordinately regulated with the cholesterol
and fatty acid biosynthetic pathways, suggesting that
IDH1 provides NADPH required by these pathways. It
was described IDH1 appears to function as a tumor sup-
pressor that, when mutationally inactivated, contributes
to tumorigenesis [22]. IDH1 is likely to function as a
tumor suppressor gene rather than as an oncogene [22].
IDH1, encoding two TCA enzymes, fumarate hydratase
(FH) and succinate dehydrogenase (SDH), has been
found to sustain loss-of-function mutations in certain
human tumors, which likewise contribute to tumor
growth via stimulating the HIF-1a pathway and muta-
tionally altering metabolic enzymes [33,34]. As IDH1 also
catalyzes the production of NADPH, it is possible that a
decrease in NADPH levels resulting from IDH1 mutation
contributes to tumorigenesis through effects on cell
metabolism and growth [17]. Zhao et al. [22] showed that
mutation of IDH1 impairs the enzyme's affinity for its
substrate and dominantly inhibits wild type IDH1 activity
Figure 1 The immunocytochemistry of IDH1 in MG63 and U2OS. 
IDH1 is specifically detected in the cytoplasm of both osteosarcoma 
cell lines MG63 and U2OS.(A) Expression of IDH1 in U2OS, × 200; (B) Ex-
pression of IDH1 in MG63,× 200; (C) Expression of IDH1 in U2OS,× 400; 
(D) Expression of IDH1 in MG63,× 400.
Figure 2 The mRNA levels of IDH1 in MG63 and U2OS (on fold). 
The mRNA levels of IDH1 is higher in U2OS than in MG63(P < 0.01).
Figure 3 The protein expression levels of IDH1 and p53 in U2OS 
and MG63. MG63 demonstrates no detectable p53 while U2OS cells 
demonstrates a high expressed p53. IDH1 expresses higher in U2OS 
than in MG63 at the protein level(P < 0.01).Hu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:43
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with the formation of catalytically inactive heterodimers.
Mutation of the IDH1 gene was strongly correlated with a
normal cytogenetic status [21].
In this study, we firstly demonstrate that IDH1 is
detected in U2OS with wild type p53 and MG63 with
mutation p53 by immnohistochemistry, Realtime-PCR
and Western Blotting. Intriguingly, our study demon-
strates that IDH1 markedly increases in U2OS compare
with MG63 not only in mRNA level but also in protein
Table 2: The expression of IDH1 and P53 in osteosarcoma biopsies
Proteins* Expression** Positive 
N***
12345 L o w H i g h
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
IDH1 4 (9.1) 2 (4.5) 15 (34.1) 10 (22.7) 13 (29.5) 21 (47.7) 23 (52.2) 40 (90.9)
P53 7 (15.9) 6 (13.6) 12 (27.3) 10 (22.7) 9 (20.5) 25 (56.8) 19 (43.2) 37 (84.1)
* P < 0.01(p = 0.000) r = 0.620, IDH1 correlates with P53 positively; Spearman's rho.
** P > 3/40.05(P = 0.316), IDH1 vs. P53; Mann-Whitney U.
*** P > 3/40.05(0.334), IDH1 vs. P53; Pearson Chis-square test;
Figure 4 The expression of IDH1 and p53 in low histological Rosen grade biopsy. IDH1 expresses at high level accompanying with high ex-
pressed p53 in Low histological Rosen grade biopsy.(A) Expression of IDH1 in low histological Rosen grade biopsy, × 100;(B) Expression of p53 in low 
histological Rosen grade biopsy, × 100; (C) Expression of IDH1 in low histological Rosen grade biopsy, × 200;(D) Expression of p53 in low histological 
Rosen grade biopsy, × 200.Hu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:43
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level. It is conceivable that the expression of IDH1 may
relate to p53.
Human osteosarcoma cell line MG63 was found with
Deletion and rearrangement of the p53 gene [35-37]. No
Wild type p53 expression could be detected in this cell
line. Our results are in accordance with the results of
Masuda et al. [6] and Mulligan et al. [36] and indicate that
inactivation of p53 is a common event in osteosarcoma
development. In addition, we authenticate the wild type
p53 in human osteosarcoma cell line U2OS in our study.
P53 is described as a tumor suppressor in many tumors.
Culotta and Koshland [38] and Harris et al [39] gave an
extensive account of its discovery and function as well as
the use of p53 in cancer risk assessment. Activity of p53
ubiquitously lost in osteosarcoma either by mutation of
the p53 gene itself or by loss of cell signaling upstream or
downstream of p53 [40]. Xue et al. [41] reported that p53
inactive may be required for maintenance of aggressive
tumors. Marion et al. [42] showed that p53 is critical in
preventing the generation of human pluripotent cells
from suboptimal parental cells. Harris and Hollstein [39]
highlighted the clinical implications of changes in the p53
gene in the pathogenesis, diagnosis, prognosis, and ther-
apy of human cancer. But, little is known about the com-
binatory role of p53 and IDH1 in OS cells. We are curious
about the role of p53 and IDH1 in osteosarcoma.
Most studies addressing the immunohistochemical
expression of IDH1 or p53 in biopsies have used a semi-
quantitative scoring approach of the staining results [43-
47], often with a 10% threshold for scoring a tumor as
positive and with a 50% threshold for scoring a tumor as
high expression level [48]. Using this approach, the
immunoreactivity for IDH1 or p53 has been used to
investigate its correlation with clinical features [47]. The
staining pattern, and thus the difference in IDH1 reactiv-
ity, is highly different among individual tumors, showing
Figure 5 The expression of IDH1 and p53 in high histological Rosen grade biopsy. IDH1 expresses at low level accompanying with low ex-
pressed p53 in high histological Rosen grade biopsy.(A) Expression of IDH1 in high histological Rosen grade biopsy, × 100;(B) Expression of p53 in high 
histological Rosen grade biopsy, × 100; (C) Expression of IDH1 in high histological Rosen grade biopsy, × 200;(D) Expression of p53 in high histological 
Rosen grade biopsy, × 200.Hu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:43
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a range from 8% through 100% IDH1-positive tumor
cells, while the P53, ranging from 5% to 100%. In addi-
tion, the positive rate of IDH1 is 90.9%, while the p53 is
84.1%. The high staining rate of IDH1 is 52.2%, while the
p53 is 43.2%. Furthermore, IDH1 expresses higher in
patients with low histological Rosen grade. IDH1 corre-
lates with metastasis negatively. There is no significant
correlation between IDH1 expression and overall sur-
v i v a l .  I n  o u r  s t u d y ,  l o w e r  I D H 1  e x p r e s s i o n  i n  h i g h e r
Rosen grade may not convey mutation in the gene. To
substitute, genetic studies of IDH1 gene alteration may be
of value. The study is limited by the fact that there were
only 44 patients and without intimate following up infor-
mation. However, it may, from the theoretical point of
view, still be valuable to study the role of IDH1 in osteo-
sarcoma. In accordance with former results, p53 in our
osteosarcoma patients correlates with histological Rosen
grade, metastasis and overall survival. In our study, the
expression of IDH1 does not correlate some other clinical
Figure 6 The immunostaining percentages of IDH1 and p53 in 
low Rosen grade vs. high Rosen grade. IDH1 expresses higher in 
Low histological Rosen grade compare with high histological Rosen 
grade at the level of the immunostaining percentages (P < 0.01), so 
does p53 (P < 0.01).
Figure 7 The immunostaining scores of IDH1 and p53 in low Ros-
en grade vs. high Rosen grade. IDH1 expresses higher in Low histo-
logical Rosen grade compare with high histological Rosen grade at the 
level of the immunostaining scores (P < 0.05), so does p53 (P < 0.01).
Figure 8 The relationship between IDH1 and survival. The IDH1 
high expression group represents the osteosarcoma patients with 
>50% IDH1 positive staining. Patients with ≤ 50% IDH1 positive stain-
ing are recorded as low-expression group. The survival time in the χ -
axis was given as years. There is no significant correlation between 
IDH1 expression and overall survival (P = 0.342).
Figure 9 The relationship between p53 and survival. The p53 high 
expression group represents the osteosarcoma patients with >50% 
p53 positive staining. Patients with ≤ 50% p53 positive staining are re-
corded as low-expression group. The survival time in the χ-axis was giv-
en as years. High-expression p53 patients have better survival than 
low-expression p53 patients do (P = 0.019).Hu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:43
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features such as age, localization of primary tumor and
histological type.
Interestingly, patients in our study with High expres-
sion of IDH1 had a very high p53 expression in osteosar-
coma biopsies, which is accordance with our result in
osteosarcoma cell lines MG63 and U2OS. A recent study
has shown IDH1 appears to function as a tumor suppres-
sor contributes to tumorigenesis in part through induc-
tion of the HIF-1 pathway [22]. Parsons et al. [20] found
that IDH1 mutations had a very high frequency of p53
mutation in human glioblastoma. Accumulation of func-
tional p53 protein followed by p53-dependent apoptosis
has been described in cultured cells exposed to hypoxia
[49]. P53 inhibits HIF-1 dependent transcription and
decrease the chances of normal cells surviving under
hypoxia since the expression of most glycolytic enzymes
is HIF-1 dependent [50]. It is conceivable that IDH1 may
relate to p53 with the function of HIF-1.
Conclusions
IDH1 may correlate with p53 and be a biomarker for
osteosarcoma correlate with histological Rosen grade and
metastasis.
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